ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Other Events
Item 8.01 Other Events.
On October 1, 2019, Ziopharm Oncology, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration has cleared an investigational new drug application submitted by MD Anderson Cancer Center for a phase 1 clinical trial to evaluate CD19-specific CAR-T therapies for patients with relapsed CD19+ leukemias and lymphomas. The clinical trial will evaluate CAR-T therapies manufactured and infused in two days or less from gene transfer using the Companys Sleeping Beauty platform. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Companys development plans for CD19-specific CAR-T therapies for patients with relapsed CD19+ leukemias and lymphomas. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Companys actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, will, could, expects, plans, anticipates, believes, and similar expressions intended to identify forward-looking statements. These statements reflect the Companys current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Any forward-looking statements set forth in this Current Report speak only as of the date of this Current Report. The Company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
|99.1||Press Release dated October 1, 2019.|